Scienture Holdings Inc.
(NASDAQ:SCNX) said Tuesday that its opioid overdose treatment Rezenopy (naloxone HCl) Nasal Spray 10 mg has been added to the formulary of a large national health plan, broadening commercial and Medicare supplemental coverage ahead of the product's planned mid-July 2026 launch.
Rezenopy Coverage Extends To More Than 100 Million Lives The company said the addition increases potential access to more than 100 million covered lives across the U.S., marking another step in its commercialization strategy for the naloxone product.
Rezenopy is the highest FDA-approved naloxone dose per nasal spray available in the U.S.
The single-use nasal spray delivers 10 mg of naloxone hydrochloride and is intended for the emergency treatment of known or suspected opioid overdose.
